A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer

Conclusions Studies comparing standard and de-escalated treatment with bone-targeted agents in breast cancer are rare. The benefits of standard treatment compared to de-escalated therapy on important clinical outcomes remain unclear. Future pragmatic studies must be conducted to determine the merits of this approach.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research